FATE - CIK 0001434316
The table below shows FATE THERAPEUTICS INC's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$106.08M | -$122.87M | -$132.26M | -$248.21M | -$162.87M | -$39.23M |
| Capital expenditure | $5.95M | $730.00K | $6.15M | $35.57M | $50.70M | $4.93M |
| Investing cash flow | $111.17M | $12.22M | $112.67M | $166.75M | -$324.02M | -$161.08M |
| Dividends paid | - | - | - | - | - |
FATE THERAPEUTICS INC reported operating cash flow of -$106.08M for fiscal year 2025. That is up 13.7% from -$122.87M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$29.82M (FY 2016) to -$106.08M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $5.49M | $99.89M | $85.00K | $9.21M | $453.13M | $282.84M |